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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of death not only in industrialized and 
developed countries but also in developing societies (WHO, 2008a). Changes in lifestyle of 
the population living in developing countries, which is due to the socioeconomic and 
cultural transition, are important reasons for increasing the rate of CVD. This observation 
has led to extensive research on prevention. Diagnosis the risk factors and predictors of 
CVD can help us detect high risk patients and prevent the disease, effectively.  
Nowadays with a rapid progress in medical technology and diagnostic tools, more predictors 
are being added to the previous list of CVD risk factors. Therefore, we need to design updated 
risk assessment methods to screen high risk individuals early in their life span. 
This chapter defines cardiovascular risk factors, classifies them, briefly describes how they 
interact, and discusses what strategies Should be implemented to prevent CVD progression. 
2. Definitions 
2.1 Coronary Heart Disease (CHD) 
Coronary heart disease (CHD) is a condition in which the walls of arteries supplying blood 
to the heart muscle (coronary arteries) become thickened. This thickening, caused by 
development of lesions in the arterial wall, is called atherosclerosis; the lesions are called 
plaques. It can restrict the supply of blood to the heart muscle (the myocardium) and may 
manifest to the patient as chest pain on exertion (angina) or breathlessness on exertion. 
(Frayn 2005). 
2.2 Cerebrovascular disease  
Cerebrovascular disease involves interruption of the blood supply to part of the brain and 
may result in a stroke or a transient ischemic attack. The loss of blood supply to part of the 
brain may lead to irreversible damage to brain tissue. The blockage most commonly arises 
from the process of thromboembolism, in which a blood clot formed somewhere else (e.g. in 
the heart or in the carotid artery) becomes dislodged and then occludes an artery within the 
brain (cerebral arteries). Narrowing of the intracerebral arteries with atherosclerotic plaque 
may increase the risk, and may also lead to local formation of a blood clot. The etiology is 
similar to that of CHD (Frayn 2005). 
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2.3 Peripheral Vascular Disease (PVD)  
Peripheral vascular disease (PVD) involves atherosclerotic plaques narrowing the arteries 
supplying other regions apart from the myocardium and brain. A common form involves 
narrowing of the arteries supplying blood to the legs. The result may be pain on exercise. In 
more severe cases, impaired blood supply leads to death of leg tissues, which requires 
amputation (Frayn 2005). 
3. Epidemiology 
3.1 Global and regional trends in CVD burden 
In recent years, the dominance of chronic diseases as major contributors to total global 
mortality has emerged (WHO, 2008a). By 2005, the total number of cardiovascular disease 
(CVD) deaths (mainly coronary heart disease, stroke, and rheumatic heart disease) had 
increased globally to 17.5 million from 14.4 million in 1990(WHO, 2009a). 
The World Health Organization (WHO) estimates there will be about 20 million CVD deaths 
in 2015, accounting for 30 percent of all deaths worldwide (WHO, 2005). Thus, CVD is today 
the largest single contributor to global mortality and will continue to dominate mortality 
trends in the future (WHO, 2009a). 
Globally, there is an uneven distribution of age-adjusted CVD mortality that is mapped in 
Figure 1. The lowest age-adjusted mortality rates are in the advanced industrialized 
countries and parts of Latin America, whereas the highest rates today are found in Eastern 
Europe and a number of low and middle income countries(WHO, 2008a). The broad causes 
for the rise and, in some countries, the decline in CVD over time are well described. The key 
contributors to the rise across countries at all stages of development include tobacco use and 
abnormal blood lipid levels, along with unhealthy dietary changes (especially related to fats 
and oils, salt, and increased calories) and reduced physical activity(Hu, 2008; ). Key 
contributors to the decline in some countries include declines in tobacco use and exposure, 
healthful dietary shifts, population-wide prevention efforts, and treatment interventions 
(Shafey et al, 2009; Davies et al, 2007). 
4. Pathophysiology 
Cardiovascular diseases, whether affecting the coronary, cerebral or peripheral arteries, 
share a common pathophysiology involving atherosclerosis and thrombosis (or clotting). 
4.1 Atherosclerosis 
Atherosclerosis is the most common cause of CVD and related mortality. The first 
observable event in the process of atherosclerosis is the accumulation of plaque 
(cholesterol from low-density lipoproteins [LDLs], calcium, and fibrin) in large and 
medium arteries. 
This plaque can grow and produce  ischemia either by insufficient blood flow if there is a high 
oxygen demand or by rupturing, forming a thrombus and occluding the lumen (Rudd et al., 
2005). Only high-risk or vulnerable plaque  forms thrombi. Characteristics of vulnerable  
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NOTE: Rates are age-standardized to WHO’s world standard population. 
SOURCES: WHO, 2009a 
Fig. 1. Age-standardized deaths due to cardiovascular disease (rate per 100,000), 2004. 
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plaque are lesions with a thin fibrous cap, few smooth muscle cells, many macrophages 
(inflammatory cells),and a large lipid core( Figure 2 ) (Rudd et al., 2005). The site of plaque 
formation or atherogenesis is the endothelium in the artery wall. Normally the endothelium 
promotes dilation of the blood vessel ,less smooth muscle cell growth, and prevention of an 
anti-inflammatory response (Davignon and Ganz, 2004). In atherosclerosis the endothelium 
becomes dysfunctional  before an atheroma or plaque, a more serious lesion, develops. This 
endothelial dysfunction results in the production of less nitric oxide, a key vasodilator, and 
the blood vessel becomes more constricted .It also becomes more permeable and allows LDL 
cholesterol to be taken up by macrophages, which then accumulate and form foam cells and 
eventually an early lesion known as a fatty streak. 
5. Risk factors for cardiovascular disease 
This section described the major risk factors for CVD in more detail. The section begins with 
lipid and inflammation-related factors, behavioral risk factors, including tobacco use, 
dietary factors, alcohol, and physical activity. This is followed by the major biological risk 
factors that mediate the role of these behaviors  leading to CVD, including obesity, blood 
pressure, blood lipids, and diabetes. 
5.1 Modifiable cardiovascular risk factors 
5.1.1 Lipid-related factors 
Lipid-related cardiovascular risk factors have attracted enormous attention over the past 
years, and consensus documents have been produced to implement treatment and 
preventive strategies. Essentially, this applies to the conventional risk factors such as high 
plasma total and low-density lipoprotein (LDL) cholesterol, low plasma high density 
lipoprotein (HDL) cholesterol and elevated plasma triglycerides. 
 
Fig. 2. Natural Progression of atherosclerosis 
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5.1.1.1 Atherogenic lipoproteins 
A number of factors determine whether a cholesterol-containing lipoprotein particle 
resident in plasma has atherogenic properties. The size of the particle determines the ease by 
which the endothelium can be penetrated; small particles are more likely to be deposited in 
the arterial wall than large particles. The binding to the subendothelial matrix is also 
dependent on size, in which the smaller particles bind more avidly to proteoglycans (Anber 
et al., 1997). The apoB protein, present as one molecule per lipoprotein particle, seems to be 
crucial. Firstly, lipoprotein particles without apoB are not atherogenic; secondly, apoB has 
multiple proteoglycan binding domains which enhance the retention of the particle in the 
subendothelial matrix (Skalen et al., 2002). Finally, physicochemical and compositional 
characteristics, such as resistance factors against oxidative stress, are likely to be important 
in reducing the modification of lipoprotein particles.  
5.1.1.2 Small, dense Low-Density Lipoprotein (LDL) 
The formation of small, dense LDL particles is complex and can be seen as a genetic trait, 
but the major gene(s) responsible remain unknown. Environmental factors also play a major 
role, in that dietary factors can influence triglyceride as a major determinant. In vitro studies 
have shown that small, dense LDL particles are formed by sequential exchange of lipids 
between LDL and triglyceride-rich lipoproteins. The cholesteryl esters contained in the core 
of the LDL particle are exchanged for triglycerides by the cholesteryl ester transfer protein 
(CETP). Triglycerides entering the LDL particle are hydrolyzed by hepatic lipase and the 
core volume of the particle is reduced. The formation of small, dense LDL is limited by the 
availability of triglyceride-rich lipoproteins, as evidenced by the close positive correlation 
between plasma triglycerides and small, dense LDL. It is assumed that these processes take 
quite some time and the end product is therefore an aged particle that has lost its defense 
against free radical attack. The retention in plasma of the particle is partly due to the fact 
that small, dense LDL has a lower affinity for the LDL receptor than normal buoyant LDL 
(Nigon et al., 1991). It is thought that a consequence of the altered chemical composition of 
the small, dense LDL particle is that it more avidly binds to the subendothelial matrix and 
upon challenge more easily undergoes oxidative modification thereby triggering foam cell 
formation (Tribble et al., 1992; Chait et al., 1993; Dejager et al., 1993;).  
The presence of triglyceride-rich lipoproteins is a principal modulator of small, dense LDL; 
the plasma concentration of the latter is strongly and positively related to the concentration 
of plasma triglycerides. In fact, all examples in which the triglyceride concentration has been 
altered to observe a change in the LDL profile are consistent: elevation of triglycerides leads 
to higher abundance of small, dense LDL; the opposite is observed when triglycerides are 
lowered, treated by diet or pharmacological agents. Low fat diets may lead to increased 
plasma triglyceride concentration; consequently a reduction in LDL size was observed in a 
study of 105 men switching from a high fat (46%) to a low fat (24%) diet (Dreon et al., 1994). 
The total LDL cholesterol concentration was, however, reduced simultaneously, so the net 
effect on cardiovascular risk is not entirely clear.  
In the Quebec Cardiovascular Study the cholesterol concentration in small dense LDL 
particle may give even more precise information. Again, in the Quebec heart study, the 
cholesterol concentration in small dense LDL particles showed the strongest association 
with the risk of CHD. These data suggest that the cholesterol within small dense LDL is 
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particularly harmful. Therefore measurement of LDL particle size and possibly cholesterol 
content within these particles may enhance our capability to predict cardiovasular events 
(Lamarche et al., 2001). 
5.1.1.3 High-Density Lipoprotein (HDL)  
HDL is another lipid profile fraction which is associated to the risk of CVD. Decreased levels 
of HDL-c correlated to increased risk of CVD. The atheroprotective role for HDL is mainly 
due to the pathway named reverse cholesterol transport (RCT). RCT is defined as the uptake of 
cholesterol from peripheral tissues back to the liver by HDL. Apo A1 is an apolipoprotein of 
the HDL that activates the enzyme lecithin-cholesteryl ester acyl-transferase (LCAT). The 
main function of LCAT is transferring cholesterol from cell to HDL. Both apo C and apo E 
on HDL are transferred to chylomicrons. 
Apo E helps receptors metabolize chylomicron remnants and also inhibits appetite (Gotoh et 
al., 2006). Therefore high HDL levels  are associated with low levels of chylomicrons; very 
low density lipoprotein (VLDL) remnants; and small dense LDLs and subsequently lower 
atherosclerotic risk. HDL has other potentially atheroprotective properties. The anti-
oxidative activity of HDL is typically characterized by its ability to inhibit LDL oxidation. It 
has also been shown to inhibit the formation of reactive oxygen species. HDL can help to 
protect endothelial cells from apoptosis induced by mildly oxidized LDL. It can affect 
platelet function through the promotion of nitric oxide production (Chen et al, 1994; Suc et 
al 1997) and coagulation by the inhibition of several coagulation factors. There is 
considerable evidence for a direct protective role of HDL in inflammatory, oxidative, 
apoptotic, and thrombotic processes. 
Major factors that increase HDL cholesterol level are exogenous estrogen, intensive exercise, 
loss of excess body fat, moderate consumption of alcohol and triglyceride lowering drugs 
such as fibrates  and niacin. Treatment of  low serum levels of HDL-C in at risk patients  is 
an important therapeutic intervention and impacts rates of disease progression as well as 
cardiovascular events (Scanu and Edelstein , 2008). 
5.1.2 Inflammation-related factors 
Inflammation is a part of atherosclerosis process, beginning with the formation of fatty 
streak underlying the endothelium of large arteries. The infiltration of monocytes and 
lymphocytes occurs as a result of the expression of adhesion molecules by endothelial cells 
lining the artery wall. Several stimuli for the inflammatory response in atherosclerosis have 
been proposed in which oxidised low-density lipoprotein (LDL), is of most importance. 
Monocytes that have infiltrated the arterial intima and differentiated into macrophages take 
up oxidized LDL through scavenger receptors in an unregulated manner, accumulating 
large amounts of cholesterol and becoming foam cells. Macrophages eventually die, through 
necrosis and apoptosis, the lipid is deposited within the core of the developing plaque 
(Figure 3). Cytokines secreted by both lymphocytes and macrophages within the plaque 
exert pro- and anti-atherogenic effects on components of the vessel wall. Smooth muscle 
cells migrate from the medial portion of the arterial wall towards the intima and secrete 
extracellular matrix proteins that form a fibrous cap. The cap separates the highly 
thrombogenic contents of the plaque lipid core from the potent coagulation system 
contained within the circulating blood. 
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This chronic, low-grade inflammation is likely to be the result of cytokines secreted by 
monocytes and soluble adhesion molecules  from the vessel wall into the circulation, where 
they subsequently act on the liver to induce the secretion of acute phase proteins, including 
C-Reactive Protein(CRP), fibrinogen and serum amyloid A (Frayn, 2005). 
 
From Frayn 2005 
Fig. 3. Schematic representation of the development of an atherosclerotic lesion, showing 
plaque rupture and platelet aggregation . 
5.1.2.1 C-Reactive protein 
Multiple studies have demonstrated that elevated levels of high-sensitivity C-reactive 
protein (hs-CRP) are associated with increased CVD risk (Buckley et al.,2009; Musunuru et 
al., 2008). hs-CRP, previously considered to be an indicator of systemic inflammation, has 
recently received much attention in the scientific literature, not only as a potential marker of 
increased atherosclerotic risk, but also as a potential target of therapy for the prevention of 
atherosclerotic CVD. Evidence derived mainly from statin trials, supports the potential 
value of CRP as a therapeutic target for both primary and secondary prevention of CVD and 
CHD. The largest study to suggest an integral role for CRP as a target for therapy in primary 
prevention of CVD is the recent Justification for the Use of Statins in Prevention: An 
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. The investigators randomized 
17,802 men ≥50 years of age and women ≥60 years of age with low LDL cholesterol levels < 
130 mg/dL and hs-CRP ≥ 2 mg/L and no history of CVD or diabetes to 20 mg rosuvastatin 
daily or placebo. The primary end point was the first occurrence of MI, stroke, 
hospitalization for unstable angina, arterial revascularization, or CV death (Ridker et al; 
2008). During the 1.9-year median follow-up duration (maximum follow-up period 5 years), 
rosuvastatin reduced LDL cholesterol by 50% and hs-CRP by 37%. Thus, JUPITER 
demonstrated a magnitude of effect larger than that of almost all prior statin trials    (Ridker 
et al; 2009). Based on the results of the JUPITER study, the U.S. Food and Drug 
Administration (FDA) in February 2010 agreed to broader labeling for rosuvastatin. 
Rosuvastatin is currently approved for the reduction of risk for stroke, MI, and 
revascularization procedures in individuals who have normal LDL cholesterol levels and no 
clinically evident CHD but who do have an increased risk based on age, CRP levels, and the 
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presence of at least one additional CVD risk factor. Accordingly, JUPITER not only 
demonstrated that hs-CRP successfully identified a population with “hidden risk” for CVD 
but also provided additional evidence for the potential utility of hs-CRP as a target for 
therapy in primary prevention of CVD disease. 
Other inflammatory states such as obesity produce elevations in CRP even in young obese 
children (Blum et al., 2005). Body mass index (BMI) is moderately correlated (r = 0.5) to CRP 
levels (Rawson et al., 2003). Recently it was demonstrated that weight loss lowers CRP 
(Tchernof et al., 2002), which provides another physiologic benefit for weight management 
as a preventive strategy for CHD reduction. Currently it is known that elevated insulin 
levels in overweight children affect CRP. Physical activity did not appear to be related 
(Rawson et al., 2003). To date few studies have investigated the effects of dietary variables 
on CRP. In a cross-sectional study, higher intakes of fruits and vegetables were associated 
with lower CRP levels (Gao et al., 2004). 
5.1.2.2 Fibrinogen 
Fibrinogen is the precursor of fibrin. As the major clotting factor in the blood  and a pro-
inflammatory molecule, fibrinogen plays role in atherosclerosis. It is synthesized in the liver 
and, like CRP, is an acute phase protein, whose circulating levels can change during acute 
responses to tissue damage or infection. Thus  Fibrinogen (Fg) is a biomarker of 
inflammation (Ross 1999), which, when elevated, indicates the presence of inflammation 
and identifies individuals with a high risk for cardiovascular disorders. Increased plasma Fg 
concentration typically accompanies hypertension development (Lominadze et al. 1998) and 
stroke (D'Erasmo et al. 1993). Factors associated with an elevated fibrinogen are smoking, 
diabetes, hypertension, obesity, sedentary lifestyle, elevated triglycerides, and genetic 
factors. Recent studies indicate that increased Fg content affects microcirculation by 
increasing plasma viscosity, RBC aggregation and platelet thrombogenesis (Lominadze et al; 
2010). These changes lead to vascular dysfunction and exacerbate microcirculatory 
complications during cardiovascular diseases (figure 4).  
 
From Lominadze et al. 2010 
Fig. 4. Schematic representation of fibrinogen-induced vascular dysfunction. 
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5.1.2.3 Serum amyloid A 
Serum amyloid A (SAA) is a precursor of amyloid A protein and comprises both 
constitutive (apoSAA1, apoSAA2) and acute phase (apoSAA4) isoforms. The serum amyloid 
A proteins are a family of inflammatory apolipoproteins with a high affinity for HDL, and 
their production by the liver and other tissues is thought to be induced by IL-1 and IL 6. 
Their role in lipid metabolism is unclear, although they may be involved in HDL trafficking. 
A small number of studies have investigated the association between SAA and the incidence 
of CHD ( Ridker et al., 1998, 2000; Danesh et al., 2000b). Taken together, these studies show 
that a comparison of individuals with values in the top third with those in the bottom third 
gives a combined risk ratio of 1.6 for CHD. However, further studies are required to 
determine whether the association is independent of possible confounders. 
5.1.3 Behavioral and lifestyle risk factors 
5.1.3.1 Tobacco 
There are currently more than 1 billion smokers worldwide. Although use of tobacco 
products is decreasing in high income countries, it is increasing globally, with more than 80 
percent of the world’s smokers now living in low and middle income countries (Jha and 
Chaloupka, 1999). 
In the Global Burden of Disease study, Lopez et al. (2006) estimated that in 2000, 880,000 
deaths from CHD and 412,000 deaths from stroke were attributable to tobacco. Smoking 
cessation has been shown to have significant impacts on reducing CHD. In a major review 
of the evidence, Critchley and Capewell (2003) determined that successful smoking 
cessation reduced CHD mortality risk by up to 36 percent. Smoking cessation leads to 
significantly lower rates of reinfarction within 1 year among patients who have had a 
heart attack and reduces the risk of sudden cardiac death among patients with CHD 
(Gritz et al., 2007). 
Two major trends are of real concern with respect to the future of tobacco-related CVD. First, 
in most parts of the world, the smoking rates are higher among the poorest populations 
(WHO, 2008b). The second worrisome trend is in smoking among girls (IOM, 2010). 
In addition to active smoking, it has become increasingly apparent that exposure to 
secondhand smoke significantly increases cardiovascular risk. A recent IOM review of the 
effects of secondhand smoke exposure concluded that exposure to secondhand smoke 
significantly increases cardiovascular risk and that public smoking bans can significantly 
reduce the rate of heart attacks. The report concluded that secondhand smoke exposure 
increases cardiovascular risk by 25 to 30 percent and that there is sufficient evidence to 
support a causal relationship between secondhand smoke exposure and acute myocardial 
infarction (AMIs). This causality was reinforced by the report’s conclusion that smoking 
bans significantly reduce the rate of AMIs, with declines ranging from 6 to 47 percent (IOM, 
2009). 
5.1.3.2 Dietary factors 
The relationship between CVD and diet is one of the most studied relationships in 
epidemiology. Although nutritional research has traditionally focused on the effect of 
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individual food groups or nutrients on CVD, there has been a shift in recent years toward 
comparing how different types of dietary patterns in their entirety affect CVD risk (IOM, 
2010). The following sections reflect this shift by discussing research on dietary factors that 
have clear impacts on CVD risk. 
5.1.3.2.1 Dietary fat 
Healthy oils are those that contain no commercially introduced trans fatty acids, are low in  
saturated fatty acids, and are high in mono- and polyunsaturated fatty acids. 
There is accumulating evidence that it is fat quality (the type of dietary fat), rather than the 
total amount of fat, that is particularly important for cardiovascular disease (Astrup, 2002). 
5.1.3.2.1.1 Saturated Fatty Acids (SFA) 
The predominant sources of SFAs are animal foods (meat and dairy). SFAs have the most 
potent effect on LDL cholesterol, which rises in a dose response fashion when increasing 
levels of SFAs are consumed. In our study, consumption of habitual hydrogenated fats and 
full-fat yoghurts (fat content more than 2.5%) increased the risk of CVD (OR = 2.12(1.23-
3.64) and 2.35(1.32-4.18), respectively) (Amani et al, 2010). These foods are the major sources 
of SFAs. SFAs intake is the principal determinant of total cholesterol(TC) and CVD and 
substitution of 1% carbohydrate calories by SFAs increases TC by 1.5 mg/dL (Joseph et al, 
2000). Of all the added fats in the diet, the most hypercholesterolemic promoting are palm 
kernel, coconut, and palm oils; lard; and butter. SFAs raise serum LDL cholesterol by 
decreasing LDL receptor synthesis and activity. Regardless of form, all fatty acids lower 
fasting triglycerides if they replace carbohydrate in the diet. In secondary prevention trials 
replacement of SFAs with MUFA, ǂ-linolenic acid, and increased fruits and vegetables 
prevented fatal and nonfatal CVD events in persons with established disease (de Lorgeril, 
1999). Thus fatty acids affect disease progression through lipids and other mechanisms and 
possibly through inflammation and thrombosis (Krummel, 2008). 
5.1.3.2.1.2 Monounsaturated Fatty Acids (MUFA) 
The American Heart Association (AHA) does not have any recommendation for the cis form 
of MUFAs (Lichtenstein et al., 2006). Oleic acid (C18:1) is the most prevalent MUFA in the 
American diet. Substituting oleic acid for carbohydrate has almost no appreciable effect on 
blood lipids; however, replacing SFAs with MUFA lowers serum cholesterol levels, LDL 
cholesterol levels, and triglyceride levels to about the same extent as polyunsaturated fatty 
acids (PUFAs ) . The effects of MUFAs on HDL cholesterol depend on the total fat content of 
the diet. When intakes of both MUFA (>15% of total kilocalories) and total fat (>35% of 
kilocalories) are high, HDL cholesterol does not change or increases slightly compared with 
levels with a lower-fat diet (Krummel , 2008). Oleic acid as a part of the Mediterranean diet 
has been shown to have antiinflammatory effects. In epidemiologic studies high-fat diets of 
people in Mediterranean countries have been associated with low blood cholesterol levels 
and CHD incidence (Trichopoulou et al., 2003). Among other factors, the main fat source is 
olive oil, which is high in MUFA. Although higher-fat diets (low in SFA with MUFAs as the 
predominant fat) can lower blood cholesterol, they should be used with caution because of 
the caloric density of high-fat diets and the results of clinical trials, which have shown new 
atherosclerotic lesions in men who consume higher-fat diets. The negative association 
between the Mediterranean diet and CHD could be the result of factors other than MUFA 
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intake. For example, these populations consume more fruits and vegetables, bread, cereals, 
fish, and nuts, and less red meat than many populations. Olive oil is the primary source of 
fat, and eggs are consumed from zero to four times per week (krummel, 2008). 
5.1.3.2.1.3 Polyunsaturated Fatty Acids (PUFA) 
The essential fatty acid linoleic acid (LA) is the predominant PUFA consumed in the 
American diet (Krummel, 2008). Population studies have demonstrated a negative 
correlation between LA intake and CHD rates (Wijendran and Hayes, 2004). Similarly, a 
meta analysis of 60 controlled human trials found that replacing PUFA for carbohydrate in 
the diet resulted in a decline in serum LDL cholesterol (Mensink et al., 2003). When SFAs are 
replaced with PUFAs in a low-fat diet, LDL and HDL cholesterol levels will be lowered. The 
lipid lowering effects of LA depend on the total fatty acid profile of the diet (Wijendran and 
Hayes, 2004). When added to study diets, large amounts of LA diminished levels of HDL 
cholesterol serum levels (Karmally, 2005). Studies suggest that high intakes of n-6 PUFAs 
may exert adverse effects on the function of vascular endothelium or stimulate production 
of proinflammatory cytokines. A low ratio of omega-6:omega-3 PUFA is recommended 
(Basu et al., 2006; Gibauer eial., 2006). 
5.1.3.2.1.4 Omega-3 fatty acids 
Fish oils, fish oil capsules, and ocean fish are rich source of the two main omega-3 fatty acids 
(i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid [DHA]). Many studies have 
shown that eating fish is associated with a decreased CVD risk. The recommendation for the 
general population for fish consumption is to eat fish high in omega-3 fatty acids (salmon, 
tuna, mackerel, sardines) at least twice a week (Psota et al., 2006). For patients who have 
CVD, 1 g of EPA and DHA combined is recommended from fish if possible but, if not, then 
from supplements (Lichtenstein et al., 2006). Patients who have hypertriglyceridemia need 2 
to 4 g of EPA and DHA per day for effective lowering (Lichtenstein et a1.,2006). Omega-3 
fatty acids lower triglyceride levels by inhibiting VLDL and apo B-100 synthesis and by 
decreasing postprandial lipemia.  
ǂ-Linolenic acid (ALA), an omega-3 fatty acid from vegetables, has anti-inflammatory 
effects. CRP levels were reduced when male patients consumed 8 g of ALA daily; similar 
results have not been observed for fish oil supplementation (Basu et a1.,2006). Omega-3 fatty 
acids also interfere with blood clotting by altering prostaglandin synthesis (Krummel, 2008). 
5.1.3.2.1.5 Trans fatty acids 
Trans-fatty acids  are produced in the hydrogenation process used in the food industry to 
increase shelf life of foods and to make margarines, firmer (Krummel ,2008). The AHA 
(Lichtenstein et al., 2006) recommends no more than 1% of calories (about 1-3 g/day) from 
trans-fatty acids. These fatty acids raise LDL cholesterol; however, effects on inflammation 
have been conflicting (Basu et a1.,2006). Most trans-fatty acids intake comes from partially 
hydrogenated vegetable oils (krummel, 2008).  
Mozaffarian et al (2007) showed that partially hydrogenated oils are extensively being used 
for cooking in Iranian homes with average per-person intake of 14 g/1000 kcal. Trans fatty 
acids (TFAs) accounted for 33% of fatty acids in these products, or 4.2% of all calories 
consumed (12.3 g/day). Consumption of hydrogenated fats was associated with higher 
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CAD risk (OR = 2.12(1.23-3.64)) in a study performed by Amani et al (2010). On the basis of 
TC:HDL-cholesterol effects alone, 9% of CHD events would be prevented by replacement of 
TFA in homes with cis-unsaturated fats (8% by replacement with saturated fats). On the 
basis of relationships of TFA intake with CHD incidence in prospective studies, 39% of CHD 
events would be prevented by replacement of TFA with cis-unsaturated fats (31% by 
replacement with saturated fats). 
5.1.3.2.1.6 Dietary cholesterol 
Dietary cholesterol raises total cholesterol and LDL cholesterol but to a lesser extent than SFAs. 
The AHA dietary patterns contain no more than 200 mg of cholesterol each day (Krummel; 
2008). There is a threshold beyond which addition of cholesterol to the diet has minimal 
effects. When cholesterol intakes reach 500 mg/day, only small increments in blood 
cholesterol occur. Cholesterol responsiveness also varies widely among individuals. Some 
people are hyporesponders (i.e., their plasma cholesterol level does not increase after dietary 
cholesterol challenge), whereas others are hyperresponders (i.e., their plasma cholesterol level 
responds more strongly than expected to a cholesterol challenge). It has been suggested that 
hyperresponders may have the apo E-4 allele and poor rates of conversion of cholesterol to bile 
acids, which causes elevated LDL cholesterol. Feedings cholesterol to animals enriches 
lipoproteins, which are atherogenic beyond just the rise in serum cholesterol (Krummel, 2008). 
SFAs and cholesterol synergistically affect LDL cholesterol level, decrease LDL receptor 
synthesis and activity, increase VLDLs enriched with apo E, increase all lipoproteins, and 
decrease chylomicron size ( which is associated with CHD risk). The effect of dietary 
cholesterol on inflammatory factors has been inconsistent (Basu et a1.,2006). 
5.1.3.2.2 Dietary sodium 
There is evident that excessive sodium intake significantly increases CVD risk and that 
reduction in sodium intake at the population level decreases CVD burden (He and 
MacGregor, 2009, IOM, 2010 ). The most well-established mechanism by which sodium 
intake increases CVD risk is increasing blood pressure (BP). Numerous studies have 
found that there is a continuous and graded relationship between salt intake and blood 
pressure. In their recent major review of sodium trends and impact, He and MacGregor 
concluded that a reduction in salt from the current global intake of 9 to 12 g/day to the 
recommended levels of 5-6 g/day would have a major impact on BP and CVD (He and 
MacGregor, 2009; IOM, 2010). Salt’s impact on CVD, however, extends beyond blood 
pressure. Animal and epidemiological studies have found that a diet high in sodium may 
directly increase the risk of stroke, which is independent and additive to salt’s effect on 
BP (He and MacGregor, 2009 ; IOM, 2010). 
5.1.3.2.3 Soy protein 
In recent years, a great deal of interest has emerged in the role of soy-bean isoflavones in 
reducing heart diseases, and isoflavones might be responsible, in part, for the ability of 
soybean to lower the risk of CVD and atherosclerosis (Anderson et al, 1995) . Anderson 
suggested that about 60-70% of the cholesterol lowering effect of soy protein may be due to 
its isoflavone content (Anderson et al, 1995). Isoflavones are a group of phytoestrogens 
which occur mainly in soy and it is consumed for the purpose of both promoting health and 
preventing several chronic diseases, including coronary heart disease, cancers of 
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reproductive organs and osteoporosis ( Lichtenstein, 1998 ; Anerson et al, 1999). Aglycone 
forms of soy isoflavones especially genistein and daidzein have greatly been studied because 
of their greater estrogenic and antioxidant activities (Arora et al, 1998). Soy isoflavones have 
been shown to decrease total, VLDL and LDL cholesterol levels while increasing HDL 
cholesterol levels in peripubertal rhesus monkeys fed soy protein-based diets (Antony et al, 
1996). It is claimed that purified isoflavones have no effect on plasma lipid and lipoprotein 
concentrations in normolipidemic subjects (Nestel et al, 1997; Hodgson et al, 1998). At present, 
there is no general agreement about the effect of soy protein isoflavones (SPI) on lipid profiles 
and moreover, it is not clear that which part of the soy protein has lipid-lowering effects. In a 
study, we designed animal model to assess the effect of SPI on serum lipid, lipoprotein profile, 
and blood sugar of experimentally- induced hypercholesterolemic rabbits,and to detect any 
dose-response effect of SPI on the above mentioned variables. In this research, the effect of soy 
protein containing 200 mg, 100 mg and a trace amount of both glycoside and aglycone forms 
of soy isoflavones were assessed in hypercholesterolemic male rabbits. Although the rabbits 
had a cholesterol-rich diet, the serum total and LDL-cholesterol remained unchanged in the 
SPI+ group (i.e. intact soy protein diet). The results have indicated that soy protein isoflavones 
maintained the serum lipid and lipoprotein levels in hypercholesterolemic rabbits kept on a 
high cholesterol diet, but alcohol-extracted (even half-dose isoflavones) soy protein diets do 
not have positive effect. Moreover, the hypocholesterolemic effect of isoflavones is not in a 
dose-response manner and it is suggested that isoflavones activity is closely related to soy 
protein (Amani et al, 2005). 
5.1.3.2.4 Fiber  
One of the potential ways by which soy protein might exert its effect on blood cholesterol is 
via its fiber content (about 6 g as non-starch polysaccharide per 100 g boiled beans), which is 
primarily soluble fiber. Soluble fiber (e.g. from oats) has been shown to lower plasma total 
and LDL-cholesterol, although the effect is small for those consuming moderate amounts 
(Truswell, 2002). In the meta-analysis by Brown et al. (1999) 2–10 g/day of soluble fiber was 
associated with a small but significant fall in total cholesterol (0.045 mmol/l per g fiber) and 
LDL-cholesterol (0.057 mmol/l per g fiber). Three apples or three (28 g) servings of oatmeal, 
providing 3 g soluble fiber, decreased total and LDL-cholesterol by about 0.13 mmol/l. The 
mechanism of this effect remains undefined. Suggestions include bile acid binding, resulting 
in an up-regulation of LDL receptors and thus increased clearance of LDL-cholesterol; 
inhibition of hepatic fatty acid synthesis byproducts of fermentation in the large bowel (e.g. 
propionate, acetate, butyrate); changes in motility or satiety; or slowed absorption of 
macronutrients resulting in improved insulin sensitivity (Brown et al., 1999). 
Consumption of diets rich in whole-grain cereals (e.g. whole-wheat cereals, whole meal 
bread and brown rice) has been associated with a lower risk of cardiovascular disease 
(Pietinen et al., 1996; Jacobs et al., 1999; Liu et al., 1999; Truswell, 2002). Vitamin E, dietary 
fibre (Richardson, 2000), resistant starch and oligosacchrarides (Cummings et al., 1992), as 
well as plant sterols (Jones et al., 1997) are some of the components of whole-grain cereals 
that may contribute to a reduced risk of heart disease (Mc Kevith (2004) . 
5.1.3.2.5 Antioxidant 
Vitamins C, E, and B-carotene have antioxidant roles in the body. Vitamin E is the most 
concentrated antioxidant carried on LDLs and its major function is to prevent oxidation of 
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PUFA in the cell membrane (Krummel, 2008). Epidemiologic studies suggest that vitamin E 
and carotenoids are inversely related to CVD, but randomized trials have not supported 
these observations (Lee et al., 2005; Lichtenstein et al., 2006). Because data have not shown 
vitamin E to be protective, the AHA does not recommend vitamin E supplementation for 
CVD prevention (Lichtenstein et al., 2006). However, RRR-a-tocopherol, the natural form of 
vitamin E, shows promise as an antiinflammatory agent (Gasu et al., 2006). Foods with 
concentrated amounts of the phytonutrients catechins, have been found to improve vascular 
reactivity. These foods are red grapes, red wine, tea (especially green tea), chocolate, and 
olive oil, and should be worked into any CVD preventive eating plan (Kay et al., 2006). In 
our case – control study, drinking tea was significantly associated with lower risk of 
coronary events (Amani et al, 2010). 
5.1.3.2.6 Stanols and sterols 
Since the early 1950s plant stanols and sterols isolated from soybean oils or pine tree oil 
have been known to lower blood cholesterol (Lichtensteine et al., 2001). Recently they have 
been esterified and made into margarines. Consuming between 2 to 3 g/day lowers 
cholesterol by 9% to 20% (Lichtenstein et al., 2001). The mechanism for cholesterol lowering 
is by inhibiting absorption of dietary cholesterol. Adult Treatment Panel III (ATP-III) 
includes stanols as part of dietary recommendations for lowering LDL cholesterol in adults. 
Because these esters can also affect the absorption of and cause lower ǃ-caroten , ǂ-
tocopherol, and lycopene levels, further safety studies are needed for use in 
normocholesterolemic individuals, children, and pregnant women (Krummel, 2008). 
5.1.3.2.7 Dietary patterns  
The effect on CVD risk of diets rich in whole grains and low in processed foods that are high in 
fat, sodium, and sugars has increasingly been investigated in both developed and developing 
countries. In parallel with economic development, radical dietary shifts toward Westernized 
diets that are high in animal products and refined carbohydrates and low in whole grains and 
other plant-based foods have occurred in many developing countries. For example in Iran, the 
results of Amani et al (2010) study showed that daily consumption of vegetable oils, tea and 
fish is significantly associated with lower risk of coronary events (odds ratio = 0.55(0.31-0.91), 
0.3(0.15-0.65), 0.23(0.13-0.42), respectively). On the other hand, it was indicated that 
consumption of hydrogenated fats and full-fat yoghurt is associated with higher risk of 
coronary artery disease (OR = 2.12(1.23-3.64) and 2.35(1.32-4.18), respectively). 
Substantial evidence has accumulated to support the notion that the traditional 
Mediterranean dietary pattern is protective against CVD . This pattern is characterized by 
an abundance of fruits, vegetables, whole grain cereals, nuts, and legumes; olive oil as the 
principal source of fat; moderate consumption of fish and lower consumption of red meat. It 
is important to note, however, that the dominance in research on the Mediterranean diet has 
come at the cost of research on other diets commonly consumed around the world that may 
also have heart health benefits (IOM , 2010). 
5.1.3.2.8 Therapeutic life style change dietary pattern (TLC) 
The ATP-III recommends the TLC dietary pattern for primary and secondary prevention of 
CHD. AHA recommends diet and lifestyle changes to reduce CVD risk in all people over the 
age of 2 years (Table 1) (Lichtenstein et al., 2006). SFA recommendations are less than 7% of 
calories; total fat content has a range of 25% to 35% of calories. 
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Consuming 30% to 35% of calories from fat while maintaining a low SFA and trans-fatty 
acid intake is the dietary pattern recommended for individuals with insulin resistance or 
metabolic syndrome. This higher fat intake, emphasizing PUFAs and monounsaturated fatty 
acids (MUFA), can be beneficial in lowering triglycerides and raising HDL cholesterol. Also, 
with a more liberal fat intake, LDL cholesterol can be lowered without exacerbating blood 
glucose levels. Increasing physical activity and decreasing energy intake to facilitate weight 
loss are critical to normalize multiple risk factors. Behavioral strategies for weight 
management to reduce cardiovascular risk have been provided by the AHA (Klein et al., 
2004). Learning outcomes include planning meals that fit the TLC plan, reading food labels, 
modifying recipes, preparing or purchasing appropriate foods, and choosing healthier 
choices when dining out. Along with the TLC dietary pattern, the Dietary Approaches to 
Stop Hypertension (DASH) pattern is also appropriate for CVD prevention and treatment  . 
Both of these dietary patterns emphasize grains, cereals, legumes, vegetables, fruits, lean 
meats, poultry fish, and nonfat dairy products.  
Because animal fats provide about two thirds of the SFAs in diet, these foods are limited. 
High-fat choices are omitted, but low-fat choices can be included. Meat is limited to 5 
oz/day, and eggs to four or fewer per week. Lean meats are high in protein, zinc, and iron; 
thus, patients who wish to consume meat, a 5-oz portion or less can be fit into the dietary 
plan if other low SFA choices are made. Neither food group has to be omitted; it is a matter 
of choice. Most people need to add the recommended two servings of fatty fish per week. 
Meeting sodium guidelines (1500 to 2300 mg daily) can be a challenge because lower-fat 
processed foods often contain salt to increase palatability. Patients may need to limit 
processed foods (Krummel 2008). 
5.1.3.3 Alcohol 
The global burden of diseases attributable to alcohol has recently been summarized; leading 
to the conclusion that alcohol is one of the largest avoidable risk factors in low and middle 
income countries (Rehm et al., 2009). Indeed, WHO estimates that the harmful use of alcohol 
was responsible for 3.8 percent of deaths and 4.5 percent of the global burden of disease in 
2004 (WHO, 2009b). Excessive alcohol intake is associated with increased risk for 
hypertension, stroke, coronary artery disease, and other forms of CVD; however, there is 
also a robust body of evidence in a range of populations suggesting light to moderate intake 
of alcohol may reduce the risk of CHD. Indeed, research suggests that the relationship 
between alcohol intake and CVD outcomes follows a “J” curve, with the lowest rates being 
associated with low to moderate intakes of alcohol (Beilin and Puddey, 2006; Lucas et al., 
2005). It is important to recognize that, as with any discussion of alcohol and health, the key 
issues are the quantity of alcohol consumed and the risk or benefit conferred by 
consumption. Although evidence indicates that low to moderate alcohol use can reduce the 
risk of CHD, excessive and harmful use clearly increases CVD risk (Beilin and Puddey, 2006; 
Lucas et al., 2005). It is important that approaches to reduce the burden of CVD not neglect 
the importance of reducing excessive alcohol consumption. 
5.1.3.4 Physical activity 
WHO and FAO have highlighted the importance of physical activity as a key determinant of 
obesity, CVD, and diabetes (Joint WHO/FAO Expert Consultation, 2003). For decades, 
evidences of the relationship between physical activity and CVD, independent of effects on 
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weight and obesity, have been strengthened. Increasing physical activity—including brisk 
walking—has been shown to decrease the risk of chronic diseases such as CHD, stroke, 
some cancers (e.g., colorectal and breast cancer), type 2 diabetes, osteoporosis, high blood 
pressure, and high cholesterol (Physical Activity Guidelines Advisory Committee, 2008) 
 
Table 1. 
Regular physical activity and higher cardiorespiratory fitness are associated with lower 
overall mortality from CVD. Men and women who are physically active experience a lower 
risk of cardiovascular disease in general and CHD in particular (US Department of Health 
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and Human Services, 1996; Wannamethee & Shaper, 2002). Furthermore, in the Nurses’ 
Health Study, a large prospective study in the USA, both brisk walking and regular 
vigorous exercise were associated with a reduction in risk of coronary events by 30–40% 
(Manson et al., 1999), and sedentary women who became active in middle age or later had a 
lower risk than their counterparts who remained sedentary . In one study performed among 
145 women with central obesity, serum concentration of HDL-c was significantly higher in 
women who do more physical activity (Sharifi et al,2008). With overall mortality, the 
epidemiological literature for CHD indicates an inverse association and a dose response 
gradient between physical activity level or cardiorespiratory fitness and incidence of CHD. 
It helps to improve several risk factors for cardiovascular disease, including raised blood 
pressure, adverse blood lipid profile and insulin resistance.  
5.1.4 Related diseases/syndrome 
5.1.4.1 Overweight and obesity 
Traditionally, obesity is defined as a BioPsychoSocial problem but in this chapter we rather 
intend to present it as an EcoBioPsychoSocioCutural issue.  
Overweight and obesity have reached epidemic proportions, not only in developed but also 
in developing countries (Sassi et al., 2009). Even in low and middle income countries where 
undernutrition is still highly prevalent, overweight and obesity—especially among 
women—is a public health problem (Caballero, 2005; Hosseinpanah et al 2009). WHO and 
FAO reviewed the evidence on the relationship between obesity and the risk of CVD and 
concluded that overweight and obesity confer a significantly elevated risk of CHD (Joint 
WHO/FAO Expert Consultation, 2003). Increased body mass index (BMI) is also associated 
with greater risk of stroke in both Asian and Western populations (WHO/FAO, 2003). The 
association between obesity and CVD is partly mediated through hypertension, high 
cholesterol, and diabetes. Abdominal or central obesity measured by waist-to-hip ratio or 
waist circumference is associated with both CHD and stroke independent of BMI and other 
cardiovascular risk factors. Even in university educated women, obesity and central fat are 
also prevalent which increase the risk of heart disease. We studied 101female staff of the 
university, aged 20-45 years. Based on the bioelectrical impedance analysis (BIA) method, 
overweight and obesity rates were determined in 34.6 and 40.6 percent of women, 
respectively, and central obesity was prevalent in 27% of them (Amani, 2007a). It is worthy 
to note that to prevent erroneous classification, localization of cut-off points can be a more 
practical way to detect individuals at greater risk of chronic disease. In a sample of 637 
married females, it was indicated that subjects in low BMI range tend to have higher fat 
percentages and they might represent a different category as overfat thin other than normal 
weight obese in Iranian women. (Amani, 2007b). 
Obesity is also an independent risk factor for other cardiovascular outcomes, such as 
congestive heart failure and sudden cardiac death. Excess energy intake is one of the key 
contributors to obesity. The lack of data limits policy makers’ abilities to focus attention on 
which dietary components lend to effective interventions that would reduce total calorie 
intake. One category that has been well studied in developed countries relates to sugar 
consumption, primarily in the form of sugar-sweetened beverages (including soft drinks, 
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juice drinks, and energy and vitamin drinks). Recent NHANES data shows that up to 5.5 
percent of dietary calories come from sugar-sweetened beverages in the United States 
(Bosire et al., 2009), which has led the American Heart Association to recommend an upper 
limit of 100 calories per day for women and 150 calories per day for men from added sugars, 
including soft drinks (Johnson et al., 2009). In some developing countries, consumption of 
sugar-sweetened beverages has increased dramatically in recent decades. Because of its 
excess caloric and sugar content, increasing consumption of sugar sweetened beverages may 
have important implications for obesity and cardiometabolic risk.  
5.1.4.2 Hypertension 
Hypertension is a risk factor for CHD, stroke, and heart failure. A recent review of the 
global burden of high blood pressure found that approximately 54 percent of stroke, 47 
percent of IHD and 25 percent of other CVDs were attributable to hypertension. Among the 
major underlying risks for hypertension are sodium, body weight, and access to treatment. 
Primary prevention focused on sodium reduction, fruit and vegetable intake, weight 
control, and avoidance of excessive alcohol intake has been shown to make a difference 
(Krummel, 2008). 
5.1.4.3 Diabetes 
Around the world, diabetes is increasingly growing and is a significant contributor to CVD 
risk. People with diabetes have more than two-fold greater risk of CVD compared to non-
diabetics (Asia Pacific Cohort Studies Collaboration, 2003). In fact, CVD is the leading cause 
of morbidity and mortality in people with diabetes (Booth et al., 2006; Kengne et al., 2007, 
2009). Individuals without established clinical diabetes, but who are at increased risk of 
developing diabetes in the future, also have a higher risk of CVD (Asia Pacific Cohort 
Studies Collaboration, 2007). Women and younger individuals with diabetes have greater 
risk of CVD. Obesity is the single most important risk factor for type 2 diabetes, but 
unhealthy diet and physical inactivity also independently raise the population risk for 
diabetes (Schulze and Hu, 2005). According to the International Diabetes Federation’s 
Diabetes Atlas 2010, the global estimated prevalence of diabetes for 2010 among people aged 
20 to 79 years will be approximately 285 million people (6.4 percent of the global 
population), of which some 70 percent will be living in developing countries (International 
Diabetes Federation, 2010). 
Diabetes is emerging as a particular concern in Asia, where more than 110 million 
individuals were living with diabetes in 2007, a large proportion of whom were young and 
middle aged. Asians tend to develop diabetes at a relatively young age and low BMI, and by 
2025 the number of individuals with diabetes in the region is expected to rise to almost 180 
million (Chan et al., 2009). Intensive glucose control reduces the risk of major cardiovascular 
events by approximately 10 percent, compared with standard treatment in people with 
diabetes. Interestingly, this benefit appeared to be independent of other cardiovascular risk 
factors (Kelly et al., 2009; Turnbull et al., 2009).  
To sum up, as with the raising obesity epidemic, the prevalence of diabetes has increased 
dramatically worldwide. It is associated with serious health consequences and is a major 
risk factor for CHD and stroke. Therefore, prevention and management of diabetes are 
critical in reducing the global burden of CVD. 
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5.1.4.4 Psychosocial risk and mental health 
Of all the psychosocial stressors associated with CVD, the link between depression and CVD 
is probably the best documented. There have been many published reviews and numerous 
meta-analyses have consistently found that depression and depressive symptoms are 
associated with an increased likelihood of developing CVD, a higher incidence of CVD 
events, poorer outcomes after CVD treatment and prevention efforts, and increased 
mortality from CVD. These associations remain consistent even after controlling for other 
CVD risk factors (Everson-Rose and Lewis, 2005; Frasure-Smith and Lesperance, 2006; 
Lesperance and Frasure-Smith, 2007; Lichtman et al., 2008). 
Behaviors that increase CVD risks are more common in depressed patients. They are more 
likely to smoke, have poor diets, and be physically inactive. Furthermore, depression has 
been found to associate with the risk of non adherence to medical treatment regimens and 
lifestyle changes, making depressed patients with CVD or high CVD risk less likely to 
adhere to prevention efforts (Lichtman et al., 2008; Ziegelstein et al., 2000). 
Chronic stress, most often studied by examining work-related stress, has been associated 
with negative behaviors such as low physical activity and poor diet, increased likelihood of 
recurrent CVD, as well as physiological consequences such as decreased heart rate 
variability. For instance, we found that the prevalence of overweight and obesity was higher 
in a sample of firefighters who may have chronic stress. Moreover they had high TC, TG 
and lipoprotein (a) and low HDL-C concentrations (Azabdaftari et al, 2009).   
Acute stress from traumatic life events such as the death of a relative, earthquakes, or 
terrorist attacks have all been associated with significant temporal increases in the incidence 
of MI (Everson-Rose and Lewis, 2005; Figueredo, 2009). 
It is clear that psychosocial factors play an important role in increasing CVD risk through both 
direct and indirect pathways. Continued research is needed to further explain the mechanisms 
by which psychosocial stressors and mental illness affect CVD risk. It is also important that 
clinicians are made aware of the effect of psychosocial factors on CVD risk, prognosis, and 
adherence to prevention efforts through improved training and knowledge expanding. 
5.2 Nonmodifiable factors 
5.2.1 Menopausal status 
Loss of estrogen following natural or surgical menopause is associated with increased CVD 
risk. Endogenous estrogen has a protective role against CVD in premenopausal women, 
probably by preventing vascular injury. Rates of CHD in premenopausal women are low 
except in women with multiple risk factors. During the menopausal period total cholesterol, 
LDL cholesterol, and triglyceride levels increase; and HDL cholesterol level decreases, 
especially in women who are overweight or obese  (Regitz-Zagrosek, 2006). 
5.2.2 Age and gender 
Age is a nonmodifiable risk factor for CHD. The increased risk for CHD parallels increase 
in age. Higher mortality rates from CHD are seen in both genders with increasing age. 
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Being older than 45 years of age is considered a risk factor for men (NCEP, 2002). For 
women the increased risk comes after the age of 55 years, which is after menopause for 
most women.  
CVD prevalence, incidence, and mortality rates tend to be higher for men than for women. 
This finding has remained consistent historically (Lawlor et al., 2001) and across countries 
and regions (Allen and Szanton, 2005; Pilote et al., 2007; WHO, 2009). 
Estrogen has a protective effect on the development of CVD risk factors and consequently is 
the reason most often cited for these gender differences (Regitz-Zagrosek, 2006). Estrogen is 
thought to contribute to premenopausal women’s tendency to have lower systolic blood 
pressure, higher levels of HDL cholesterol, and lower triglyceride levels than men ( Pilote et 
al., 2007). 
The lower prevalence of smoking among women is another factor that could contribute to 
their decreased CVD incidence and mortality rates. Around the world, the prevalence of 
female smoking is lower than that of men (Pilote et al., 2007). Although rates of smoking, 
dyslipidemia, and hypertension are generally lower among women than men, women tend 
to have less favorable profiles for other key CVD risk factors. Worldwide, women are more 
likely to be sedentary than men (Guthold et al., 2008). Some researchers have suggested that 
women’s social status in many cultures and their lack of leisure time due to childcare and 
other familial responsibilities likely contribute to their lower levels of physical activity 
(Brands and Yach, 2002; Pilote et al., 2007). 
Another troubling gender difference is the increased prevalence of obesity among women. 
WHO data indicate that although overweight (BMI ≥ 25 kg/m2) is more common among 
men globally; obesity (BMI ≥30 kg/m2) is more common among women. 
A number of different reasons have proposed by CVD researchers that why women might 
delay seeking medical attention, receive delayed treatment, and experience poorer outcomes 
during and after an MI or stroke. One often-cited reason that women tend to wait longer to 
seek treatment is that many do not perceive themselves as being at risk (Jensen and Moser, 
2008). 
Because of the robust evidence indicating gender differences in CVD incidence, morbidity, 
and outcomes, these differences, as well as the unique needs of women, should be 
considered when developing CVD research priorities, policies, and health service 
interventions. 
6. Association between early life factors and subsequent risk for CVD 
6.1 Low birth weight and adult cardiovascular disease  
Ther is growing evidence in developing and developed countries ,based on cohort studies, 
that fetal and early childhood periods is important in the onset of CVD later in life (Victora 
et al., 2008; Walker and George, 2007; WHO, 2009c). The influences during this period 
include maternal factors during pregnancy, such as smoking, obesity, and malnutrition, and 
factors in infancy and early childhood, such as breastfeeding, low birth weight, and 
undernutrition. 
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Maternal smoking during pregnancy has been linked to CVD-related risk factors. It has been 
consistently associated with increased childhood obesity independent of other risk factors 
(Oken et al., 2008). A number of studies have examined the effects of maternal obesity on the 
body weight of their children; however, the evidence is inconsistent. Two cohort studies in the 
United States found that excessive weight gain or maternal obesity during pregnancy was 
associated with overweight and obesity in the children at ages 3 and 4 years (Gillman et al., 
2008; Whitaker,2004). Similarly, a cohort study in Finland found that mothers’ body mass 
index (BMI) was positively associated with their sons’ BMI in childhood (Eriksson et al., 1999). 
Another factor that appears to influence risk for long-term cardiovascular health is 
breastfeeding. Breastfeeding has been found to not only reduce childhood morbidity and 
mortality but also to be weakly protective against obesity later in life (Bhutta et al., 2008; 
Gluckman et al., 2008). 
Undernutrition in infancy, especially when followed by rapid weight gain, is associated 
with increased risk of CVD and diabetes in adulthood (Barker and Bagby, 2005; Caballero, 
2005; Gluckman et al., 2008 ). This phenomenon is known as the developmental origins 
theory of CVD. It means that if disruptions to the nutritional, metabolic, and hormonal 
environment at critical stages of development are happened, it may lead to permanent 
“programming” of the body’s structure, physiology, and metabolism that translate into 
pathology and disease, including CVD, later in life (Barker, 1997, 1998, 2007). The exact 
physiological mechanisms through which this programming occurs are not yet fully 
elucidated; however, there is evidence that fetal and early postnatal undernutrition can 
cause metabolic, anatomic, and endocrine adaptations that affect the hypothalamic-
pituitary-adrenal axis, lipoprotein profiles, and end organ glucose uptake, among other 
processes (Prentice and Moore, 2005). Support for the developmental origins theory of CVD 
comes from a number of retrospective, and more recently prospective, cohort studies in 
various populations. Studies in the United Kingdom, the United States, Finland, and India 
found that fetal undernutrition  followed by a rapid catch-up growth from childhood to 
early adolescence was significantly associated with the later development of CVD in both 
men and women (Barker et al., 2005; Eriksson et al., 1999; Osmond and Barker, 2000). Early 
undernutrition followed by catch-up growth during childhood has also been associated 
with subsequent hypertension and type 2 diabetes (Barker, 1998; Osmond and Barker, 2000) 
This emerging data on the effects of rapid weight gain after early undernutrition have 
prompted some researchers to suggest a shift from the original “fetal origins” hypothesis to 
an “accelerated postnatal growth hypothesis” of CVD (Singhal et al., 2003, 2004). 
The emerging evidence on the association between low birth weight followed by rapid 
growth in childhood and subsequent risk for CVD raises important considerations for 
addressing global CVD because low birth weight and exposure to undernutrition in utero 
and in infancy are common in many developing countries (Caballero, 2009; Kelishadi, 2007). 
The acquisition and accumulation of risk for CVD continues in childhood and adolescence 
(Celermajer and Ayer, 2006 ). Unhealthful lifestyle practices such as consumption of high 
calorie and high fat foods, tobacco use, and physical inactivity begin in childhood, 
introducing major behavioral risks for CVD. Childhood adversity also influences adult 
cardiovascular health. In addition, there is also an emerging body of evidence on the 
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presence of biological risk factors in children and youth, including pathophysiological 
processes associated with heart disease that can be seen as early as childhood. 
6.2 Childhood obesity and CVD risk 
Childhood obesity is associated with multiple risk factors for CVD, which are amplified in 
the presence of overweight and persist from childhood into adulthood. These risk factors 
include hyperlipidemia, high blood pressure, impaired glucose tolerance and high insulin 
levels, as well as metabolic syndrome. It has been estimated that 60 percent of overweight 
children possess at least one of these risk factors that can lead to CVD in adulthood 
(Freedman et al., 1999). This is especially important in terms of implications for global CVD 
because the prevalence of childhood obesity is increasing in developing countries (WHO, 
2008a). 
7. Public health approach to cardiovascular disease risk reduction 
7.1 Cardiovascular disease as a public health problem 
The prevention of cardiovascular disease is a major public health challenge for a number of 
years around the world. Although death rates have been falling in many westernized 
countries (e.g. USA, Australia, UK), rates are rising rapidly elsewhere. 
7.2 Current dietary recommendations for primary prevention 
Dietary recommendations tend to be country specific and are based on the available 
evidence. 
The ATP-III recommends the TLC dietary pattern for primary and secondary prevention of 
CHD. In agreement, the AHA recommends diet and lifestyle changes to reduce CVD risk in 
all people over the age of 2 years (Lichtenstein et al., 2006). 
As is evident, knowledge about the role of diet in risk factor reduction and reducing the risk 
of cardiovascular events themselves continues to expand. It is now recognized that CVD risk 
can be mediated through multiple biological pathways other than only serum total and LDL 
cholesterol or dietary factors. With this in mind, it is necessary to modify the dietary advice 
offered to those with an increased risk of CVD. 
7.3 Health promotion in children and other subgroups of the population 
Health aspects present in childhood, such as blood lipids, body weight and blood pressure 
may track into adulthood. Therefore, a useful health strategy is the adoption of sensible 
eating habits and an active lifestyle early in childhood. It is important to promote 
cardiovascular health in childhood by increasing physical activity and preventing or 
treating obesity, raised blood pressure, insulin resistance and type 2 diabetes (Williams et al., 
2002). Current nutritional recommendations for the general population are applicable for 
most children over 5 years and can be gradually applied from the age of 2 years. It is also 
recommended that all children and adolescents participate in physical activity for 1 hour 
daily which should be of at least moderate intensity (Fox & Riddoch, 2000). The 
implementation of guidelines and success of health strategies require input from the 
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governments, health professionals, the food industry and teachers, as well as the children 
themselves and their parents. Moreover, social and cultural influences must be recognized 
when designing and implementing strategies. 
8. Summary 
• Cardiovascular disease is the leading cause of death worldwide, accounting for around 
18 million deaths each year. 
• Modifiable risk factors for cardiovascular disease include atherogenic lipoproteins, 
inflammatory related factors behaviors, lifestyle and chronic diseases such as obesity, 
diabetes and hypertension. 
• Non modifiable risk factors include menopause, age and gender.  
• There is evidence that a chronic, low-grade inflammation underlies atherosclerosis, 
although it is not clear whether this is a cause or effect phenomenon. 
• The acute phase proteins, C-reactive protein (CRP), fibrinogen and serum amyloid A, 
appear to be associated with risk for cardiovascular disease. 
• The advantages of a dietary pattern approach rather than individual dietary 
components can influence plasma cholesterol levels and may also affect other emerging 
risk factors. 
• Physical activity has great impact on CVD risk reduction when it is accompanied by 
dietary pattern changes. 
• Low birth weight and low weight gain during infancy are associated with an increased 
risk of adult cardiovascular disease, hypertension, type 2 diabetes and the insulin 
resistance syndrome. 
9. Future research 
Future research is required to establish the strength of the associations between the 
emerging risk factors described in this chapter and cardiovascular disease, in order to 
compare their predictive value with the established risk factors. For example, further work 
is required to evaluate the independence of many of the novel risk factors for cardiovascular 
disease and whether these associations are causal. In addition, more information is needed 
about how these novel risk factors might be modified by different aspects of the diet. As 
indicated in ancient Traditional Persian Medicine (TPM), understanding the effect of 
individual foods on the trend of heart disease and hyperlipidemias can be leading fields of 
study in the near future. 
Moreover, local modified risk factors should be defined and addressed to track the patients 
at greater risks in more applicable ways. 
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